Karo Pharma’s $360 Million Acquisition of Trimb


White & Case LLP has advised listed EQT portfolio company Karo Pharma AB on its SEK 3.4 billion (US$360 million) acquisition of Trimb Holding from Avista Capital Partners and other shareholders.

The transaction is subject to approval from the relevant authorities.

Karo Pharma is a specialty pharma company, which develops and markets products for pharmacies as well as directly to the healthcare sector. Karo Pharma is listed on Nasdaq Stockholm and is majority owned by EQT.

Stockholm-based Trimb owns licenses to, markets and sells a large number of over-the-counter pharmaceuticals and consumer healthcare products. It has around 90 employees and its product portfolio includes brands such as Flux, Nailner and Pevaryl.

Avista Capital Partners is a leading New York-based private equity firm with more than US$6 billion invested in more than 30 growth-oriented healthcare businesses.

The White & Case team which advised on the transaction was led by partner Jan Jensen (Picture) and associate Patrik Erblad (both Stockholm), and included partners Oscar Liljeson, Johan Thiman (both Stockholm), Axel Schulz (Brussels) and Marc Israel (London), counsel Peter Svanqvist (Stockholm) and Sophie Sahlin (Brussels), and associates Victor Åberg, Rebecka Tenenbaum, Ivana Sutalo, Petar Bojovic (all Stockholm) and Rebecca Yourstone (London).

Involved fees earner: Victor Aberg – White & Case; Petar Bojovic – White & Case; Patrik Erblad – White & Case; Marc Israel – White & Case; Jan Jensen – White & Case; Oscar Liljeson – White & Case; Sophie Sahlin – White & Case; Axel Schulz – White & Case; Ivana Sutalo – White & Case; Peter Svanqvist – White & Case; Rebecka Tenenbaum – White & Case; Johan Thiman – White & Case;

Law Firms: White & Case;

Clients: Karo Pharma AB ;